MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Gesloten

1.2 -2.44

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.18

Max

1.25

Belangrijke statistieken
By Trading Economics
Inkomsten	-51K -928K
EPS	-0.254
Werknemers	2
EBITDA	-51K -928K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-7M 4.4M
Vorige openingsprijs	3.64
Vorige sluitingsprijs	1.2

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 apr 2026, 23:26 UTC

Populaire aandelen

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 apr 2026, 20:41 UTC

Belangrijke Marktbewegers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 apr 2026, 23:49 UTC

Marktinformatie

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 apr 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline After Hitting Record High -- Market Talk

16 apr 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 apr 2026, 22:51 UTC

Marktinformatie

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 apr 2026, 22:08 UTC

Winsten

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Health Care Roundup: Market Talk

16 apr 2026, 20:49 UTC

Winsten

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 apr 2026, 20:43 UTC

Winsten

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:40 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

16 apr 2026, 20:40 UTC

Marktinformatie

Winsten

Netflix Says Engagement Quality Hits New High -- Market Talk

16 apr 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 apr 2026, 20:25 UTC

Winsten

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:23 UTC

Winsten

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 apr 2026, 20:19 UTC

Winsten

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 apr 2026, 20:17 UTC

Winsten

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 apr 2026, 20:17 UTC

Winsten

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.